secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001048477-25-000088
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance
--------------------------------------------------------------------------------

- Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).
- Non-GAAP diluted EPS $1.44 (+50%); N-GAAP operating margin 39.9% (up 8.7pp Y/Y).
- VOXZOGO revenue $221M (+20%) and Enzyme Therapies $555M (+15%); KUVAN down 7% to $27M.
- Raised FY2025 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.
- Completed Inozyme acquisition (July); BMN 333 (achondroplasia) Phase 2/3 to start 1H'26; BMN 390 discontinued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/0001048477-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/bmrn-20250804.htm
  HTML page:      https://secwatch.observer/filing/0001048477-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer